
Podcast
Introduction of Food to Infants: Preventing Peanut Allergies - Frankly Speaking EP3
This week, I sit down with Dr. Robert Baldor to discuss some of the intricacies of asthma. In addition to outlining the pathophysiology of asthma, we provide practical ways to classify the disease and avoid risk factors with the goal of decreasing exacerbations. Can peanut allergy be prevented in children? This podcast episode will review the newest AAP recommendations on feeding in the first year of life, with a special emphasis on preventing atopic disorders. Our objectives will be to review feeding recommendations, discuss methods to decrease risk of atopic disorders in high risk children and consider future research in pediatric feeding recommendations.
Episode references and resource links:
- Greenhawt M, Fleischer D, Chan ES, et al. LEAPing Through the Looking Glass: Secondary Analysis of the Effect of Skin Test Size and Age of Introduction on Peanut Tolerance after Early Peanut Introduction. Allergy. 2016; doi: 10.1111/all.13100. https://www.ncbi.nlm.nih.gov/pubmed/27896827
- LEAPing Through the Looking Glass: Secondary Analysis of the Effect of Skin Test Size and Age of Introduction on Peanut Tolerance after Early Peanut Introduction (Online article)
- Fleischer DM, Sicherer S, Greenhawt M, et al. Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants. 2015; PEDIATRICS Volume 136, number 3 http://pediatrics.aappublications.org/content/136/3/600
- Togias, A, Cooper, S, Acebal, ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. Annals of Allergy, Asthma, & Immunology. 2016; 16: S1206-1206. doi:http://dx.doi.org/10.1016/j.anai.2016.10.004 http://www.annallergy.org/article/S1081-1206(16)31164-4/fulltext
Already listened on another platform?
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 2/1/2017
Expiration Date: 2/1/2017
Topics
Faculty

Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA

Robert A. Baldor, MD, FAAFP
Professor and Chairman, Dept of Family Medicine
UMass Medical School/Baystate
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Frank J. Domino, MD: Has disclosed no relevant financial relationships.
Robert A. Baldor, MD, FAAFP: Has disclosed no relevant financial relationships.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.